Refractory aspergillus pneumonia in patients with acute leukemia: Successful therapy with combination caspofungin and liposomal amphotericin

Cancer

Volumn 97, Issue 4, 2003, Pages 1025-1032

  Aliff, Timothy B ^a   Maslak, Peter G ^a   Jurcic, Joseph G ^a   Heaney, Mark L ^a   Cathcart, Kathleen N ^a   Sepkowitz, Kent A ^a   Weiss, Mark A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Amphotericin B; Aspergillosis; Caspofungin; Leukemia

Indexed keywords

ALKALINE PHOSPHATASE; AMPHOTERICIN B LIPID COMPLEX; CASPOFUNGIN;

ACUTE LEUKEMIA; ADULT; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPERGILLUS; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG INDICATION; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HOSPITAL DISCHARGE; HUMAN; KIDNEY FAILURE; LIVER TOXICITY; MALE; NEPHROTOXICITY; PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL RATE; TREATMENT OUTCOME;

ACUTE DISEASE; ADULT; AGED; AMPHOTERICIN B; ANTI-BACTERIAL AGENTS; ASPERGILLOSIS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LEUKEMIA; LUNG DISEASES, FUNGAL; MALE; MIDDLE AGED; PEPTIDES; PEPTIDES, CYCLIC; PNEUMONIA; RETROSPECTIVE STUDIES;

EID: 0037441932     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11115     Document Type: Article

References (34)

1. Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998;26:781-803.
2. Yoshida M, Tsubaki K, Kobayashi T, et al. Infectious complications during remission induction therapy in 577 patients with acute myeloid leukemia in the Japan Adult Leukemia Study Group studies between 1987 and 1991. Int J Hematol. 1999;70:261-267.
3. Bodey G, Bueltmann B, Duguid W, et al. Fungal infections in cancer patients: an international autopsy survey. Eur J Clin Microbiol Infect Dis. 1992;11:99-109.
4. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 1996;33:23-32.
5. Schwartz RS, Mackintosh FR, Schrier SL, Greenberg PL. Multivariate analysis of factors associated with invasive fungal disease during remission induction therapy for acute myelogenous leukemia. Cancer. 1984;53:411-419.
6. Wiley JM, Smith N, Leventhal BG, et al. Invasive fungal disease in pediatric acute leukemia patients with fever and neutropenia during induction chemotherapy: a multivariate analysis of risk factors. J Clin Oncol. 1990;8:280-286.
7. Bow EJ, Loewen R, Cheang MS, Schacter B. Invasive fungal disease in adults undergoing remission-induction therapy for acute myeloid leukemia: the pathogenetic role of the antileukemic regimen. Clin Infect Dis. 1995;21:361-369.
8. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis. 2000;30:696-709.
9. Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect. 1998;37:173-180.
10. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, Huebner K. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect. 1996;33:23-32.
11. Bow EJ. Invasive aspergillosis in cancer patients. Oncology. 2001;15:1035-1039.
12. Gerson SL, Talbot GH, Hurwitz S, Strom BL, Lusk EJ, Cassileth PA. Prolonged granulocytopenia: the major risk factor for invasive pulmonary aspergillosis in patients with acute leukemia. Ann Intern Med. 1984;100:345-351.
13. Greene JN. Catheter-related complications of cancer therapy. Infect Dis Clin North Am. 1996;10:255-295.
14. Denning DW. Therapeutic outcome in invasive aspergillosis. Clin Infect Dis. 1996;23:608-615.
15. Franzot SP, Casadevall A. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob Agents Chemother. 1997;41:331-336.
16. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH. In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob Agents Chemother. 2002;46:245-247.
17. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34:7-14.
18. Caillot D, Couaillier JF, Bernard A, et al. Increasing volume and changing characteristics of invasive pulmonary aspergillosis on sequential thoracic computed tomography scans in patients with neutropenia. J Clin Oncol. 2001;19:253-259.
19. Bennett JE. Aspergillus species. In: Mandell GL, Douglas RG, Bennett JE, editors. Principles and practice of infectious diseases, 3rd ed. New York: Churchill Livingstone, 1990:1958-1962.
20. Franquet T, Muller NL, Gimenez A, Guembe P, de La Torre J, Bague S. Spectrum of pulmonary aspergillosis: histologic, clinical, and radiologic findings. Radiographics. 2001;21:825-837.
21. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. 1997;15:139-147.
22. Barnes AJ, Oppenheim BA, Chang J, Morgenstern GR, Scarffe JH. Early investigation and initiation of therapy for invasive pulmonary aspergillosis in leukaemic and bone marrow transplant patients. Mycoses. 1999;42:403-408.
23. von Eiff M, Roos N, Fegeler W, et al. Pulmonary fungal infections in immunocompromised patients: incidence and risk factors. Mycoses. 1994;37:329-335.
24. Burch PA, Karp JE, Merz WG, Kuhlman JE, Fishman EK. Favorable outcome of invasive aspergillosis in patients with acute leukemia. J Clin Oncol. 1987;5:1985-1993.
25. Stevens DA, Lee JY. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch Intern Med. 1997;157:1857-1862.
26. Denning DW, Lee JY, Hostetler JS, et al. NIAID mycoses study group multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med. 1994;97:135-144.
27. Boogaerts M, Winston DJ, Bow EJ, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med. 2001;135:412-422.
28. Scheven M, Schwegler F. Antagonistic interactions between azoles and amphotericin B with yeasts depend on azole lipophilia for special test conditions in vitro. Antimicrob Agents Chemother. 1995;39:1779-1783.
29. Kontoyiannis DP, Lewis RE, Sagar N, May G, Prince RA, Rolston KV. Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: an E-test-based strategy. Antimicrob Agents Chemother. 2000;44:2915-2918.
30. Schaffner A, Bohler A. Amphotericin B refractory aspergillosis after itraconazole: evidence for significant antagonism. Mycoses. 1993;36:421-424.
31. Caspofungin Aspergillus study group. Cancidas - in the treatment of invasive aspergillosis. Protocol 019: an analysis of efficacy, safety, and tolerability. Available at from URL: http://www.merck.com/product/usa/cancidas/hcp/clinical_studies/ protocol_019.pdf [accessed May 15, 2002].
32. Reichenberger F, Habicht J, Matt P, et al. Diagnostic yield of bronchoscopy in histologically proven invasive pulmonary aspergillosis. Bone Marrow Transplant. 1999;24:1195-1199.
33. McCabe RE, Brooks RG, Mark JB, Remington IS. Open lung biopsy in patients with acute leukemia. Am J Med. 1985;78:609-616.
34. Ribrag V, Dreyfus F, Venot A, Leblong V, Lanore JJ, Varet B. Prognostic factors of invasive pulmonary aspergillosis in leukemic patients. Leuk Lymphoma. 1993;10:317-321.